SG59971A1 - Pyridazino quinoline compounds - Google Patents

Pyridazino quinoline compounds

Info

Publication number
SG59971A1
SG59971A1 SG1996007261A SG1996007261A SG59971A1 SG 59971 A1 SG59971 A1 SG 59971A1 SG 1996007261 A SG1996007261 A SG 1996007261A SG 1996007261 A SG1996007261 A SG 1996007261A SG 59971 A1 SG59971 A1 SG 59971A1
Authority
SG
Singapore
Prior art keywords
phenyl
deriv
substd
opt
furyl
Prior art date
Application number
SG1996007261A
Other languages
English (en)
Inventor
Thomas Michael Bare
Richard Bruce Sparks
James Roy Empfield
Timothy Wayne Davenport
Jeffrey Alan Mckinney
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of SG59971A1 publication Critical patent/SG59971A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG1996007261A 1993-10-22 1994-10-20 Pyridazino quinoline compounds SG59971A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds

Publications (1)

Publication Number Publication Date
SG59971A1 true SG59971A1 (en) 1999-02-22

Family

ID=26303731

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1996007261A SG59971A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds
SG9900943A SG92630A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG9900943A SG92630A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Country Status (29)

Country Link
US (3) US5744471A (fr)
EP (2) EP0724583B1 (fr)
JP (1) JP3583132B2 (fr)
KR (1) KR100261209B1 (fr)
CN (1) CN1053189C (fr)
AT (2) ATE198072T1 (fr)
AU (2) AU688393B2 (fr)
CA (1) CA2171332A1 (fr)
CZ (1) CZ292311B6 (fr)
DE (2) DE69426422T2 (fr)
DK (2) DK1004582T3 (fr)
ES (2) ES2154686T3 (fr)
FI (2) FI113865B (fr)
GB (1) GB9420590D0 (fr)
GR (1) GR3035080T3 (fr)
HU (1) HUT74161A (fr)
IL (1) IL111266A (fr)
MY (2) MY124316A (fr)
NO (1) NO306995B1 (fr)
NZ (2) NZ275472A (fr)
PL (1) PL180679B1 (fr)
PT (2) PT724583E (fr)
RU (1) RU2168511C2 (fr)
SG (2) SG59971A1 (fr)
SI (2) SI1004582T1 (fr)
SK (1) SK282491B6 (fr)
TW (1) TW406082B (fr)
UA (1) UA60291C2 (fr)
WO (1) WO1995011244A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9507318D0 (en) 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
EP1577311A1 (fr) * 1999-12-23 2005-09-21 AstraZeneca AB Sels de composé pyridazino quinoline et utilisation dans le traitement de la douleur
EP1244453A1 (fr) * 1999-12-23 2002-10-02 AstraZeneca AB Methode et composition pour traiter la douleur
EP1244660B1 (fr) * 1999-12-23 2006-03-22 AstraZeneca AB Procedes et compositions pour le traitement de la douleur
ATE274513T1 (de) * 1999-12-23 2004-09-15 Astrazeneca Ab Verbindungen und verfahren zur behandlung von schmerz
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
AU2566201A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Compounds and methods for the treatment of pain
HUP0300313A3 (en) * 1999-12-23 2007-05-02 Astrazeneca Ab Compound, pharmaceutical composition containing it and its use for the treatment of pain
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
BR0016646A (pt) * 1999-12-23 2002-10-08 Astrazeneca Ab Método para tratar um paciente que sofre de dor, e, composição farmacêutica
US20050124622A1 (en) * 1999-12-23 2005-06-09 Brown Dean G. Compounds and methods for the treatment of pain
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
DE60119949T2 (de) 2000-09-29 2007-04-26 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE ANWENDUNG IN DER BEHANDLUNG VON SCHMERZEN
AU2001292500A1 (en) * 2000-09-29 2002-04-08 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
JP2004509964A (ja) * 2000-09-29 2004-04-02 アストラゼネカ・アクチエボラーグ 7−クロロ−4−ヒドロキシ−2−(2−ピリジルエチル)−1,2,5,10−テトラヒドロピリダジノ[4,5−b]キノリン−1,10−ジオン及び疼痛治療のためのその使用
EP1325005A1 (fr) * 2000-09-29 2003-07-09 AstraZeneca AB 1,2,5,10-tetrahydropyridazino 4,5-b]quinoline-1,10-diones et leur utilisation pour le traitement de la douleur
EP1390349B1 (fr) 2001-05-31 2012-07-25 Sanofi Derives d'aminoquinoline et d'aminopyrridine et leur utilisation comme ligands d'adenosine a3
EP1655301B1 (fr) 2003-08-04 2015-03-11 Valery Khazhmuratovich Zhilov Bioisostères cycliques issus d'un système purine et composition pharmaceutique à base desdits bioisostères
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2881078C (fr) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l'atp
WO2007075901A2 (fr) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Promedicaments de modulateurs de transporteurs abc
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2819670B1 (fr) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Composition pharmceutique et leurs administrations
CA2963945C (fr) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-cristaux de modulateurs du regulateur de conductance transmembranaire de la mucoviscidose

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
HUT74161A (en) 1996-11-28
DE69434380T2 (de) 2006-05-04
SI1004582T1 (fr) 2005-08-31
JPH09504519A (ja) 1997-05-06
IL111266A (en) 2002-03-10
FI961696A0 (fi) 1996-04-18
IL111266A0 (en) 1994-12-29
CA2171332A1 (fr) 1995-04-27
UA60291C2 (uk) 2003-10-15
CN1053189C (zh) 2000-06-07
WO1995011244A1 (fr) 1995-04-27
AU7944094A (en) 1995-05-08
FI970907A0 (fi) 1997-03-03
DE69434380D1 (de) 2005-06-23
AU6899998A (en) 1998-07-30
KR100261209B1 (ko) 2000-09-01
ES2154686T3 (es) 2001-04-16
FI113865B (fi) 2004-06-30
CZ113896A3 (en) 1996-09-11
DE69426422D1 (de) 2001-01-18
MY132875A (en) 2007-10-31
HK1013997A1 (en) 1999-09-17
MY124316A (en) 2006-06-30
EP1004582A3 (fr) 2000-08-30
NZ329303A (en) 2000-01-28
JP3583132B2 (ja) 2004-10-27
PT724583E (pt) 2001-03-30
CZ292311B6 (cs) 2003-09-17
EP0724583A1 (fr) 1996-08-07
SK50496A3 (en) 1997-03-05
FI114916B (fi) 2005-01-31
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
US6103721A (en) 2000-08-15
DE69426422T2 (de) 2001-05-10
RU2168511C2 (ru) 2001-06-10
DK0724583T3 (da) 2001-03-05
ES2241513T3 (es) 2005-11-01
HU9600889D0 (en) 1996-06-28
CN1138332A (zh) 1996-12-18
PL180679B1 (en) 2001-03-30
GB9420590D0 (en) 1994-11-30
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
NZ275472A (en) 1998-03-25
NO306995B1 (no) 2000-01-24
PL314041A1 (en) 1996-08-05
US6232313B1 (en) 2001-05-15
ATE295846T1 (de) 2005-06-15
ATE198072T1 (de) 2000-12-15
AU688393B2 (en) 1998-03-12
FI970907L (fi) 1997-03-03
EP1004582B1 (fr) 2005-05-18
NO961584D0 (no) 1996-04-19
GR3035080T3 (en) 2001-03-30
EP0724583B1 (fr) 2000-12-13
DK1004582T3 (da) 2005-08-15
AU721139B2 (en) 2000-06-22
SG92630A1 (en) 2002-11-19
US5744471A (en) 1998-04-28
SK282491B6 (sk) 2002-02-05
EP1004582A2 (fr) 2000-05-31
FI961696L (fi) 1996-04-18

Similar Documents

Publication Publication Date Title
GB9420590D0 (en) Pyridazino quinoline compounds
TW370529B (en) Pyrazolopyrimidines
ATE206412T1 (de) Heterocyclische verbindungen als bradykinin antagonisten
DE69720965D1 (de) Chinazolinderivate und deren verwendung als vegf hemmer
EA199900927A1 (ru) Трициклические соединения
ES8600288A1 (es) Un procedimiento para la preparacion de derivados de quinolina.
MY132405A (en) Quinazoline derivatives
TW224972B (fr)
GR3030506T3 (en) 1-azaadamantane derivatives as 5-ht agonists or antagonists.
SE9904177D0 (sv) Novel compounds
GB2254613B (en) Anti-cancer anthracene compounds
DE69316392D1 (de) Azanoradamantane
HU900728D0 (en) Process for preparation of calcium antagonistics
FR2342063A2 (fr) Nouveaux acetamidoximes, leur procede de preparation et leur application en therapeutique
FI954340A7 (fi) Menetelmä uusien terapeuttisesti käytt¦kelpoisten 5-substituoitu tia-sykloalka-ÄdÜ-1,2,4-triatsoloÄ1,5-aÜpyrimidiinijohdannaisten valmistamiseksi